Improved Immunotherapy of a Recombinant Carcinoembryonic Antigen Vaccinia Vaccine When Given in Combination with Interleukin-2

摘要: Interleukin-2 (IL-2) has been an effective immune modulator in several active-specific immunotherapy experimental protocols using either viral or oncolysate-based vaccines. In this report, data indicate that IL-2 administration can appreciably augment the therapeutic effect of a single immunization recombinant vaccinia virus-carcinoembryonic antigen (rV-CEA) vaccine CEA-expressing syngeneic murine model system. A rV-CEA C57BL/6 mice bearing palpable CEA-positive colon adenocarcinoma tumors results complete tumor regression approximately 20% mice. The addition course low-dose 60-70% Moreover, combination and induces systemic immunity, which protects those tumor-free from subsequent rechallenge with cells. No such protection was observed immunized wild-type (V-Wyeth) alone alone. Cellular assays revealed to significantly increased CEA-specific T-cell proliferative responses as well cytolytic when compared enhanced response, coupled improved outcome following administration, suggests treatment cytokine may effectively substitute for multiple immunizations clinical directed at tumors.